Dr. Mark Lee Spencer

Co-author (with Dr. Amelia T. Murphy) of the 2110 TIGR-Tas paper — a nanoscale gene-editing delivery platform targeting neurodegenerative protein-aggregation disorders, developed at Dome 1. The platform demonstrated 100% clinical success in trial but was not commercialized due to existing Earth-side standard-of-care treatments.

Not involved in the subsequent Dome 4 pivot to radiation repair or the founding of Nova Biosciences.